Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03839940 · ClinicalTrials.gov registry record · Phase 3
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Terminated
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT03839940 is a Phase 3 study that was terminated before completion, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 39 participants.
The verdict
NCT03839940, a Phase 3 study, was terminated before completion, sponsored by Alliance for Clinical Trials in Oncology.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- DRUG Everolimus
- DRUG Dexamethasone
- OTHER Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2022-08-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03839940
The ClinicalTrials.gov registry entry for NCT03839940 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03839940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03839940 about?
NCT03839940 is a clinical study titled "Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer". This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.
What is the current status of trial NCT03839940?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2019-06-03. Estimated completion is 2022-08-03.
What interventions are being tested in trial NCT03839940?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Everolimus (DRUG), Dexamethasone (DRUG), Questionnaire (OTHER).
Who is sponsoring clinical trial NCT03839940?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.